Navigation Links
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
Date:1/9/2009

DUBLIN, Ireland, January 9 /PRNewswire/ -- Azur Pharma Limited ("Azur Pharma") today announced that it licensed the exclusive U.S. marketing rights for Niravam(R) (alprazolam orally disintegrating tablets), Parcopa(R) (carbidopa-levodopa orally disintegrating tablets), Kemstro(TM) (baclofen orally disintegrating tablets) and Fluxid(TM) (famotidine orally disintegrating tablets) from UCB (Euronext: UCB). Financial terms were not disclosed.

Niravam, Parcopa and Kemstro are central nervous system ("CNS") products. Azur Pharma's CNS business currently markets FazaClo(R) in the U.S. for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenia drug treatments. FazaClo is supplied as an innovative orally disintegrating tablet that uses proprietary formulation technologies licensed from CIMA Labs Inc. ("CIMA"), a subsidiary of Cephalon Inc (NASDAQ: CEPH).

Mr Seamus Mulligan, Chairman and Chief Executive of Azur stated, "We are pleased to add these valuable products to our portfolio. In particular, Niravam, Parcopa and Kemstro represent a broadening of our CNS franchise and are consistent with our approach of improving our products through the application of value added drug delivery technologies."

Niravam and Parcopa have been commercially available in the U.S. since 2005 and 2004, respectively. There is one approved generic competitor to Parcopa. Two ANDAs to Niravam have been filed with the FDA. Kemstro and Fluxid are both FDA approved but not yet commercially available in the U.S.

About Azur Pharma

Azur is a privately held pharmaceutical company dedicated to enhancing patients' lives by developing and marketing pharmaceutical products in specialist therapeutic areas. Azur's strategy is to identify, evaluate, selectively ac
'/>"/>

SOURCE Azur Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... The next-generation sequencing (NGS) clinical market is poised for huge ... industry. BCC Research reveals in its new report that the market drivers of this ... growing need for better diagnostics as part of a molecular diagnostics trend. , The ...
(Date:7/1/2015)... HAMILTON, Bermuda , July 1, 2015 /PRNewswire/ ... biopharmaceutical company focused on the treatment of dementia, ... investor briefing on July 22 at 5:45 p.m. ... at the Alzheimer,s Association International Conference 2015 (AAIC). ... following remarks: , Dr. Lawrence ...
(Date:7/1/2015)... PHILADELPHIA , July 1, 2015 ... technology will ... s evidence-based clinical s olutions suite ... scientific, technical and medical information products and services, announced today ... -based clinical decision support (CDS) technology company. InferMed,s ...
(Date:7/1/2015)... 1, 2015  UCB, a multinational biopharmaceutical company, ... leader in designing, transforming, and running intelligent business ... recognition of their close collaboration in driving transformation ... business services (GBS) finance organization. The ... that work together effectively to embrace the innovative ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... Fluorescence activated cell sorting (FACS) is a , tool ... individual cells using fluorescent probes that bind specifically to molecules , ... cells of a given population down to the level of a ... Figure 1.Linear Amplification from 1-1000 Cells. , ...
... Isolate and Enrich for ... Isolating Bacterial RNA for Microarray Analysis , The rapid increase in , ... several years has opened up a new ... analysis using DNA microarray technology. In recent , ...
... NEW Cyanobacterial Module , ... MICROB Express (patent pending) is currently the , ... novel strategy that rapidly removes >95% of the 16S and 23S rRNA from , ... species , (Figure 1). MICROB Express can ...
Cached Biology Technology:Cells-to-cDNA II Using FACS Sorted Cells 2Bacterial Whole Genome Array Analysis 2Bacterial Whole Genome Array Analysis 3Bacterial Whole Genome Array Analysis 4Bacterial Whole Genome Array Analysis 5Bacterial Whole Genome Array Analysis 6Bacterial Whole Genome Array Analysis 7Bacterial mRNA Isolation, Fast and Easy 2Bacterial mRNA Isolation, Fast and Easy 3
(Date:6/18/2015)... June 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market announces that its Wocket® ... on "Money on the Mark", scheduled to air on WABC ... June 20 th . The broadcast air- ... 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/16/2015)... CITY , June 16, 2015 /CNW Telbec/ ... their partnership centralized around the incorporation of handyem,s ... point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented model ... BIO International Conference at the Pennsylvania ... from June 15 th to 18 ...
(Date:6/15/2015)... 2015 A new report [ ... majority of US consumers using mobile banking applications want their ... fingerprint and voiceprint, instead of having to prove who they ... " Mobile Identity   -   The Fusion of Financial ... now the primary channel used by Gen X and Gen ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... damage that normally heals on its own will not ... land that release industrial chemicals, fuel oils and other ... colleagues have found. , UCF associate professor of biology ... Institute, Broward County Department of Environmental Protection, the College ...
... Wolbachia have long been interested in its ability to proliferate. ... of its insect hosts and genetically tricking them to bear ... Now, a new study from the MBL (Marine Biological ... demonstrates that a virus common to Wolbachia cells may be ...
... Neuroscientists at the Case Western Reserve University School ... in the brain's immune cells triggers a cascade ... that eventually leads to the neural cell death ... their findings in the Journal of Biological Chemistry ...
Cached Biology News:Pollution threatens coral health by preventing lesions from healing, UCF study shows 2Pollution threatens coral health by preventing lesions from healing, UCF study shows 3Viral hitchhiker inhibits Wolbachia bacteria's ability to proliferate 2Case Western Reserve University researchers find protein associated with brain cell death 2
... emerging as a powerful new tool for ... only amino groups have been able to ... as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and its ... to the protein interaction tool chest that ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... Nonanoyl-N-methylglucamide White solid. ... be readily removed by dialysis. Useful ... ≥98% by HPLC. Absorbance (10%, ... 2 O. CMC 19 - 25 ...
...
Biology Products: